JMP (Outperform) boosts its price target on Acadia Pharmaceuticals (ACAD +3.2%) to $27 from $16....

|By:, SA News Editor

JMP (Outperform) boosts its price target on Acadia Pharmaceuticals (ACAD +3.2%) to $27 from $16. SA contributor PTSD Trader recently said pimavanserin is the "silver lining in the company's playbook."